相关实验视频
Updated: Jul 17, 2025

14:57
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
9.6K
通过计算和基于细胞的研究,类素作为结构突变p53Y220C的潜在活性剂
Lakshay Malhotra1,2, Punit Kaur1, Abdul Samath Ethayathulla1
1Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India.
Journal of biomolecular structure & dynamics
|August 29, 2023
概括
某些类黄,特别是MPA和MPB,可以恢复p53 Y220C癌症突变的功能. 这些化合物显示出稳定突变的p53蛋白的治疗潜力,可以用于癌症治疗.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- p53 Y220C突变是人类癌症中常见的结构变化,导致瘤抑制活性丧失.
- 这种突变使p53蛋白不稳定,允许溶剂进入其DNA结合域,从而创建一个可准的裂.
- 以前的研究表明,黄素能够恢复胰腺癌细胞中的p53 Y220C功能.
研究的目的:
- 评估六种库尔库明类黄类药物 (阿皮基宁, 异基基宁, 液基宁, 卢托林, MPA 和 MPB) 在恢复 p53 Y220C 突变的功能方面的潜力.
- 研究这些黄类药物与p53 Y220C突变体相互作用的分子机制.
- 评估这些化合物在诱导p53 Y220C突变的癌细胞中诱导细胞毒性的体外疗效.
主要方法:
- 分子对接模拟以预测p53 Y220C裂内的结合相互作用.
- 分子动力学 (MD) 模拟分析 p53 DNA 结合域在化合物相互作用时的稳定性.
- 基于细胞的细胞毒性测试使用具有p53 Y220C突变的BxPC-3胰腺癌细胞.
主要成果:
- 医学模拟表明,测试的黄类药物可以稳定突变的p53DNA结合域,使其形成类似野生类型的结构.
- 黄类药物甲基甲 (MPA) 和甲基甲 (MPB) 显示出显著的细胞毒性,在BxPC-3细胞中在100μM时导致75%的细胞死亡.
- 这些发现表明,在p53 Y220C突变体上,MPA和MPB的结构恢复机制存在.
结论:
- 黄酸MPA和MPB在恢复p53Y220C突变的功能方面具有治疗潜力.
- MPA和MPB可以作为p53 Y220C突变的癌症的新疗法.
- 这些化合物在组合疗法策略中可能是有价值的,以提高疗效和减少药物剂量.
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
DNA Damage can Stall the Cell Cycle
9.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K
Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
Negative Regulator Molecules
35.4K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K
In-vitro Mutagenesis
14.0K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
14.0K

